BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Jeff Collins will participate on a panel titled "Funding Innovation, Cross-Border Investments and M&A Trends" at the US India BioPharma & Healthcare Summit in Cambridge, MA
News | 05. 14. 2009
